ADAR and hepatocellular carcinoma: Recently, Chen et al. [15] described direct involvement of ADAR editing in human hepatocellular carcinoma (HCC), showing how the transcripts of an oncoprotein degrader and confirmed contributor to HCC pathology, antizyme inhibitor 1 (AZIN1), are modified at specific sites by ADAR1, and that ADAR1 is commonly upregulated in HCC patient tumors resulting in even higher AZIN1 editing frequency and poorer prognosis.